---
title: A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
nct_id: NCT00415428
overall_status: COMPLETED
sponsor: "Pfizer's Upjohn has merged with Mylan to form Viatris Inc."
study_type: OBSERVATIONAL
primary_condition: Heart Diseases
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00415428.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00415428"
ct_last_update_post_date: 2021-02-18
last_seen_at: "2026-05-12T07:17:50.213Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

**Official Title:** Patient And Physician Alliance -Guideline Education Treatment Optimization

**NCT ID:** [NCT00415428](https://clinicaltrials.gov/study/NCT00415428)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2776
- **Lead Sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Conditions:** Heart Diseases, Diabetes Mellitus, Type 2
- **Start Date:** 2007-01
- **Completion Date:** 2008-09
- **CT.gov Last Update:** 2021-02-18

## Brief Summary

The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subjects had to meet all of the inclusion criteria to be eligible for enrollment into the study. The following subjects qualify for inclusion in the study:
* Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL) cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned independently of this observational study and for whom baseline values were or became available.
* Subjects with known CVD diagnosed \> or = 6 months before inclusion
* Previous myocardial infarction
* Ischemic heart disease (stable and unstable angina pectoris)
* Ischemic apoplexy
* Peripheral arterial disease
* And/Or
* Subjects with T2D diagnosed \> or = 6 months before inclusion
* At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be \<6 months before inclusion.

Exclusion Criteria:

* Subjects presenting with any of the following were not to be included in the study:
* Life expectancy of \< or = 2 years
* Unable/unwilling to understand/follow instructions
* Taking part in a clinical study involving an investigational drug
* Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study
```

## Arms

- **1.**

## Interventions

- **Patient adherence to national educational guidelines.** (BEHAVIORAL)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00415428.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00415428*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*